Bank of America analyst Allen Lutz lowered the firm's price target on GoodRx Holdings Inc. to $2.60 from $3 on January 5. The firm kept an Underperform rating on the shares.
For the broader drug distributor sector, however, the firm remained positive heading into 2026. It adjusted its price targets to align with recent changes in valuation multiples across the peer group.
Morgan Stanley reduced its price target for GoodRx from $5 to $4 on December 18. The firm maintained an Equal Weight rating.
In a 2026 outlook for the Healthcare Services sector, Morgan Stanley noted that healthcare tech and providers offer an attractive backdrop for alpha-generation. The managed care segment continues to struggle, the firm said.
Barclays initiated coverage of GoodRx with an Underweight rating and a $3 price target on December 8.
While establishing a Neutral outlook on the broader US healthcare tech and distribution industry, Barclays expressed the most optimism toward drug distributors. In contrast, the firm maintained a more cautious and mixed perspective on the dental and healthcare IT sub-sectors.
GoodRx Holdings Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the US.